As Theresa May’s trigger finger gets itchy – article 50 is due to be activated by the end of the month – the lion’s share of intrigue will be  on how the next two years might alter Irish-UK trade relations. Photograph: Bloomberg

MONDAY Results: YouGov Indicators: Euro zone labour cost index and wage growth (Q4) Meetings: Girls in Tech launch event (Bank of Ireland, Grand(...)

Mainstay Medical’s has announced the first sale of its ReActiv8 neurostimulator to treat chronic lower back pain  at a hospital in Koblenz, Germany

Mainstay Medical, the Irish developer of a breakthrough device to treat chronic lower back pain, has made its first commercial sale. The company’s Re(...)

Mainstay Medical chief executive Peter Crosby. Photograph: Nick Bradshaw

Medical device firm Mainstay Medical has sought approval to market in Australia its implantable device for chronic low back pain. The Dublin-listed(...)

Early-stage companies raised seed capital of €57m  in the first nine months of this year, equivalent to 8%  of all funds raised

Investment in Irish technology firms has more than doubled over the last two years, according to new figures which show that companies raised a record(...)

Mainstay Medical’s chief executive Peter Crosby: The company  raised €30 million in funding in June through a placing of new shares in the business, with the money to be used to drive the commercialisation of its flagship neurostimulator ReActiv8

Dublin-listed Mainstay Medical, developers of an implantable device that targets chronic lower-back pain, has added another US patent to its portfoli(...)

Peter Crosby, CEO of Mainstay Medical. The company is targeting chronic lower back pain with an implantable device

Dublin-listed Mainstay Medical, a company targeting chronic lower back pain with an implantable device, has reported an operating loss of almost $8 mi(...)

Mainstay Medical chief executive Peter Crosby.

Dublin-listed Mainstay Medical, a company targeting chronic lower back pain with an implantable device, reported a $13.2 million (€11.8 million) loss(...)

Peter Sandys, managing partner at Seroba Life Sciences, and Aidan Meagher, head of life sciences at EY: “It is essential that we continue to nurture high potential start-ups and give them the opportunity to grow their business”

At an event in Dublin this week, more than 50 medtech start-ups will pitch for funding from venture capital firms with more than €13 billion in funds (...)

Peter Crosby, chief executive of Mainstay Medical

Dublin-listed Mainstay Medical, which is targeting chronic lower back pain with an implantable device, has drawn down €10.5 million of the €15.5 milli(...)

The trial results are encouraging, with the highlight for Mainstay Medical being the 90 per cent of patients who report an improvement in quality of life after six months of using the surgically implanted device.

Anyone will chronic lower back pain will tell you just how disabling it can be. That’s why investors are excited by the prospects for a new approach b(...)

  • « First
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »